Form 10-Q Alexza Pharmaceuticals For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Roth Capital Downgrades Alexza Pharma (ALXA) to Neutral
August 8, 2014 6:44 AM EDTRoth Capital downgraded Alexza Pharma (NASDAQ: ALXA) from Buy to Neutral with a price target of $5.50 (from $10.00).
For an analyst ratings summary and ratings history on Alexza Pharma click here. For more ratings news on Alexza Pharma click here.
Shares of Alexza Pharma closed at $4.86 yesterday.
... MoreAlexza Pharmaceuticals, Inc. (ALXA) Posts Q2 Loss of 34c/Share
August 7, 2014 4:39 PM EDTAlexza Pharmaceuticals, Inc. (NASDAQ: ALXA) reported Q2 EPS of ($0.34), $0.33 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.24 million.
For earnings history and earnings-related data on Alexza Pharmaceuticals, Inc. (ALXA) click here.
... More